Form 4: Elicio Therapeutics Director Jay Venkatesan Reports Acquisition of Common and Pre-Funded Warrants

Director Jay Venkatesan reports the acquisition of common and pre-funded warrants in Elicio Therapeutics, Inc.

Summary

• On June 28, 2024, Jay Venkatesan, a director of Elicio Therapeutics, Inc., reported the acquisition of common and pre-funded warrants.
• The common warrants are exercisable at $5.00 per share starting July 1, 2024, and expire on July 1, 2029.
• The pre-funded warrants are exercisable at $0.01 per share starting July 1, 2024, and do not have an expiration date.
• The reporting person may be deemed to have shared voting and investment power over the trust which holds these securities.
• A member of the reporting person's immediate family is the beneficiary of the trust which holds these securities.
• The reporting person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of warrant acquisitions, with no inherent positive or negative implications for the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider transactions, allowing investors to monitor the actions of company insiders like directors and officers.

Stakeholder Impact

• Shareholders may be interested in the insider's activity, as it can reflect their confidence in the company's future prospects.

Key Dates